N	Concordance
1	olved without relapse after intravenous immunoglobulin therapy, which was admini
2	mmunoglobulin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infecte
3	hange was unsuccessful, but intravenous immunoglobulin (IVIG) led to complete re
4	f treatment with commercial intravenous immunoglobulin (IVIG). Herein, we report
5	f GBV-C/HGV by contaminated intravenous immunoglobulin since GBV-C/HGV RNA was n
6	s with the use of high-dose intravenous immunoglobulin (IVIG) in the treatment o
7	vity (ACA) of aggregates in intravenous immunoglobulin preparations (IVIG) was i
8	sults indicate that monthly intravenous immunoglobulin infusion (IVIG) appears t
9	rted therapeutic benefit of intravenous immunoglobulin in patients with chronic 
10	odel to study the effect of intravenous immunoglobulin (IVGG) on the placental t
11	 lymphocyte immunization or intravenous immunoglobulin is under evaluation in co
12	ed following treatment with intravenous immunoglobulin infusion and high-dose co